Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528123 | 0.85 | KMT2A (0.39) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL5535665 | 0.80 | MEN1 (0.48) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL5523981 | 0.74 | CTSK (0.34) | ALDH1A1TDP1 | |
| SCHEMBL14597022 | 0.74 | KMT2A (0.39) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL13935665 | 0.71 | ALDH1A1 (0.41) | KMT2AALDH1A1MEN1LMNAL3MBTL1 | |
| SCHEMBL5523923 | 0.70 | MEN1 (0.47) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL5530256 | 0.68 | MEN1 (0.47) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL5530279 | 0.64 | CTSK (0.34) | ALDH1A1TDP1 | |
| SCHEMBL5999032 | 0.64 | MAPT (0.49) | KMT2AALDH1A1MEN1LMNATDP1 | |
| SCHEMBL14597023 | 0.62 | MEN1 (0.46) | KMT2AALDH1A1MEN1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637555-B2 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1683794-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | Arena Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1599469-B1 | TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217562-A1 | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof | SQLE, ACE, AGTR2 | KMT2A 4044/4885ALDH1A1 681/4885MEN1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.